---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000048"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:36:20.841348+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint

## Summary
- Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.
- Net loss $49.5M ($0.46 loss per share); adjusted EBITDA $(29.1)M.
- 3,639 active patients on therapy as of Sept 30, 2023; prescriptions up 6% YoY to 1,467.
- Phase 3 INNOVATE-3 (ovarian cancer) did not meet primary overall survival endpoint at final analysis.
- Cash & short-term investments $921.2M; gross margin 75%.

## SEC filing metadata
- accession: 0001645113-23-000048
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/nvcr-20231026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000048
- JSON: https://secwatch.observer/filing/0001645113-23-000048.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000048.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported the quarter ended September 30, 2023 results: revenue $127.3 million, net income Net loss for the quarter was $49.5 million with loss per share of $0.46, EPS $0.46.
  - Period: the quarter ended September 30, 2023
  - Revenue: $127.3 million
  - Net income: Net loss for the quarter was $49.5 million with loss per share of $0.46
  - EPS: $0.46
  - Result: reported results
  source text: Total net revenues for the quarter were $127.3 million, a decrease of 3% compared to the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.